Loading…
This event has ended. Visit the official site or create your own event on Sched.
View analytic
Sunday, September 17 • 7:00am - 9:00am
Industry-Supported Symposia: Advances in the Management of Tardive Dyskinesia

Sign up or log in to save this to your schedule and see who's attending!

Feedback form is now closed.
Breakfast will be served. Seating for these sessions is available on a first-come, firstservedbasis. Admittance is based on availability and is not guaranteed. Please plan toarrive early to ensure a seat. Breakfast will only be available until 8 A.M.

Research into tardive dyskinesia (TD) pathophysiology and treatment targetshas led to the advancement of vesicular monoamine transporter 2 (VMAT2)inhibitors, with one agent recently approved by the FDA and the other grantedbreakthrough therapy designation. Key differences in the pharmacokinetic/pharmacodynamic properties of these newer agents will be examined, as wellas clinical outcome data from the ARM-TD, AIM- TD, KINECT-3, the ongoingKINECT-4, and other clinical trials.

Supported by an educational grant from Teva Pharmaceuticals.

Sunday September 17, 2017 7:00am - 9:00am
La Nouvelle Orleans AB The New Orleans Ernest N. Morial Convention Center, 900 Convention Center Boulevard New Orleans, LA 70130